New York, NY -- (SBWIRE) -- 09/27/2018 -- B-cell maturation antigen (BCMA), an important biomarker of the B-cells, has emerged as a promising therapeutic target for the treatment of multiple myeloma and other hematological malignancies. The antigen is universally expressed on the surface of multiple myeloma cells. The research focus shifted towards BCMA targeted therapies in 2004, when the role of BCMA was first indicated in the progression of multiple myeloma. It is the second most common type (13%) of all hematological malignancies. The disease proves to be fatal due to serious complications associated with it and the frequent events of re-occurrence of illness. The widespread presence of multiple myeloma and other related B-cell malignancies demands confident diagnosis and treatments. Hence, there is an immediate need for effective therapies for proper medical care.

Get sample copy of this report at: https://www.researchnreports.com/request_sample.php?id=90759

Key companies covered as a part of this study include Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd

Currently, researchers are actively involved in developing three major types of immunotherapies (classified by product class) targeting BCMA; these are chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies and antibody drug conjugates (ADCs). Several biopharmaceutical companies have been active in this area since last few years while others have recently stepped in. A number of strategic partnerships have also been inked between various stakeholders to advance R&D activities in this domain. Results of preclinical and clinical studies have demonstrated the potential benefits of this class of therapies; the major highlight being their attractive safety profile.

Key features of the study:

This report provides an in-depth analysis of the global B cell mature antigen (BCMA) targeted therapeutic market and provides pipeline analysis for the same

It explains the potential opportunities across various sectors and explains the attractive investment offer matrix for this market. Provides valuable insight into market drivers, redemption, opportunity, impact analysis, core development and competitive landscape.

Profiles leading players in the global B-cell mature antigen (BCMA) target treatment market based on company profile, financial performance, product pipeline, geographic presence, and key development.

Get discount at: https://www.researchnreports.com/ask_for_discount.php?id=90759

A portion of the main players operating in the worldwide BCMA Targeted Therapies advertise are profiled in the report with the end goal of point by point contextual analysis. The business and budgetary diagram of these organizations alongside their key strategies embraced have been given in this report.

For more enquiry: https://www.researchnreports.com/enquiry_before_buying.php?id=90759

Table of Contents

Global BCMA Targeted Therapies Market Research Report 2018

Chapter 1 Global BCMA Targeted Therapies Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global BCMA Targeted Therapies Market Competition by Manufacturers
Chapter 4 Global Production, Revenue (Value) by Region
Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions
Chapter 6 Global Production, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
Chapter 11 Market Effect Factors Analysis